Rituximab Noninferior to Ocrelizumab in Relapsing MS
Rituximab is noninferior to ocrelizumab in suppressing disease activity in newly diagnosed multiple sclerosis, with a similar incidence of adverse events, a new trial shows.
Medscape Medical News
source https://www.medscape.com/viewarticle/rituximab-noninferior-ocrelizumab-relapsing-ms-2026a1000nij?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/rituximab-noninferior-ocrelizumab-relapsing-ms-2026a1000nij?src=rss
Comments
Post a Comment